Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-42160443 adjunctive therapy for cancer-related pain
NL-OMON34218Phase 2Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer pain comparing JNJ-42160443 + standard pain therapy with Placebo + standard pain therapy (2 arms). Primary endpoint: Change from baseline to end of double-blind phase in average cancer-related pain intensity. Planned start Jul 2010; status: withdrawn.
02
Drugs
fulranumab
03
Conditions
cancer pain
Beyond the preview
Go deeper on NL-OMON34218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34218.